TrialPLoS neglected tropical diseases2026

Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants.

Mischka Moodley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.